Nationwide Fund Advisors Has $2,084,000 Stake in PerkinElmer, Inc. (PKI)
Nationwide Fund Advisors held its stake in PerkinElmer, Inc. (NYSE:PKI) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 30,579 shares of the medical research company’s stock at the close of the 2nd quarter. Nationwide Fund Advisors’ holdings in PerkinElmer were worth $2,084,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also modified their holdings of PKI. Envestnet Asset Management Inc. lifted its holdings in PerkinElmer by 28.1% during the first quarter. Envestnet Asset Management Inc. now owns 1,979 shares of the medical research company’s stock worth $115,000 after acquiring an additional 434 shares during the period. Ameritas Investment Partners Inc. bought a new stake in PerkinElmer during the first quarter worth $152,000. LS Investment Advisors LLC lifted its holdings in PerkinElmer by 2.1% during the second quarter. LS Investment Advisors LLC now owns 2,877 shares of the medical research company’s stock worth $196,000 after acquiring an additional 60 shares during the period. Capital Asset Advisory Services LLC bought a new stake in PerkinElmer during the second quarter worth $222,000. Finally, Cipher Capital LP bought a new stake in PerkinElmer during the second quarter worth $230,000. Institutional investors and hedge funds own 91.47% of the company’s stock.
WARNING: “Nationwide Fund Advisors Has $2,084,000 Stake in PerkinElmer, Inc. (PKI)” was originally published by Daily Political and is the property of of Daily Political. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.dailypolitical.com/2017/10/16/nationwide-fund-advisors-has-2084000-stake-in-perkinelmer-inc-pki.html.
A number of brokerages recently commented on PKI. Citigroup Inc. reiterated a “buy” rating and set a $80.00 price target (up from $74.00) on shares of PerkinElmer in a report on Tuesday, September 26th. Goldman Sachs Group, Inc. (The) reiterated a “neutral” rating and set a $67.00 price target on shares of PerkinElmer in a report on Tuesday, September 26th. Morgan Stanley reiterated an “overweight” rating and set a $77.00 price target (down from $79.00) on shares of PerkinElmer in a report on Friday, October 6th. Zacks Investment Research upgraded PerkinElmer from a “hold” rating to a “buy” rating and set a $74.00 price target on the stock in a report on Tuesday, August 1st. Finally, Wells Fargo & Company began coverage on PerkinElmer in a report on Thursday, July 13th. They set a “market perform” rating and a $72.00 price target on the stock. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have given a buy rating to the company. PerkinElmer presently has an average rating of “Hold” and a consensus price target of $67.77.
Shares of PerkinElmer, Inc. (NYSE:PKI) opened at 71.39 on Monday. The firm has a 50-day moving average price of $68.78 and a 200-day moving average price of $64.95. PerkinElmer, Inc. has a 52-week low of $45.35 and a 52-week high of $72.11. The stock has a market capitalization of $7.87 billion, a P/E ratio of 21.53 and a beta of 0.72.
PerkinElmer (NYSE:PKI) last released its quarterly earnings results on Thursday, August 3rd. The medical research company reported $0.67 earnings per share for the quarter, meeting the consensus estimate of $0.67. The firm had revenue of $547.00 million for the quarter, compared to analysts’ expectations of $554.14 million. PerkinElmer had a return on equity of 13.44% and a net margin of 16.80%. The company’s revenue was up 2.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.67 EPS. On average, analysts predict that PerkinElmer, Inc. will post $2.89 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 10th. Stockholders of record on Friday, October 20th will be paid a $0.07 dividend. The ex-dividend date of this dividend is Thursday, October 19th. This represents a $0.28 annualized dividend and a dividend yield of 0.39%. PerkinElmer’s dividend payout ratio (DPR) is 8.46%.
PerkinElmer Company Profile
PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.
Receive News & Ratings for PerkinElmer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.